in the clinic for 1 week after each vaccine is administered. The vaccination 
sites will be assessed for the presense of Induration, erythema, tenderness, 
ulceration, or infection. Patients' temperatures and vital signs will also be 
monitored. The area of erythema and induration will be measured. Vaccination 
sites will be excised as described above under local anesthesia in sterile 
fashion using a 4-6mm punch biopsy knife. The specimens will be divided into 
thirds. One third will be snap frozen in OCT medium and used for In situ 
hybridization (appendix 19.5) and immunohistochemistry (appendix 19.6). Another 
portion (1/3) will be prepared for electron microscopy (appendix 19.7). The 
remaining third will be placed in tissue culture with 6000 IU/ml IL-2 and 
complete medium . 
[504] 
Recombinant DNA Research, Volume 16 
